Urine Cancer Risk Test "MySignal®︎" Now Available at 323 Stores Including Drugstores "Wants," "Wellness," and "Tsuruha Drug" in Kyushu (Excluding Okinawa)

Craif Inc. (Location: Shinjuku-ku, Tokyo; CEO: Ryuichi Onozaki; hereinafter referred to as Craif), a bio-AI startup, has announced that Tsuruha Group Drug & Pharmacy West Japan Co., Ltd. (Headquarters: Hiroshima City, Hiroshima Prefecture; President: Shoichi Murakami; hereinafter referred to as TGN), which operates the drugstore chains "Wants," "Wellness," and "Tsuruha Drug" in Kyushu (excluding Okinawa), will begin offering Craif's urine cancer risk test "MySignal®︎" at some of its stores.

Products Handled

MySignal Scan

MySignal Light

<Stores Handling Products>

Chugoku Area: 291 stores

Kyushu Area: 32 stores

About the "MySignal Series"

The "MySignal Series" is a cancer risk test that leads to prevention and early detection. This series includes "MySignal Scan," a test that evaluates the risk of 10 types of cancer, including pancreatic cancer, with high accuracy using microRNA x AI; "MySignal Light," a test that evaluates cancer risk more easily; "MySignal Navi," a gene test specialized for cancer; and "MySignal Check," a test that monitors and leads to the prevention of DNA damage. All tests can be performed without burdening the body, simply by collecting urine or saliva. Through these four tests, we support the prevention of onset by knowing one's constitutional risk and monitoring daily DNA damage. It is a comprehensive cancer countermeasure aimed at promoting cancer prevention and early detection by supporting the early detection of cancers that cannot be prevented, in an integrated manner.

For details, please visit the website.

https://misignal.jp/

The MySignal series is not a medical device. It determines risk by statistically calculating analyzed information and is not a substitute for a "diagnosis" of whether one has contracted cancer as a medical act. Even if the risk is determined to be low, it does not guarantee that cancer is absent or that cancer will not occur in the future.

About Craif

Craif is a bio-AI startup founded in 2018, dedicated to the early detection of cancer. By integrating its proprietary analysis technology platform "NANO IP®︎ (NANO Intelligence Platform)," which detects various biomarkers such as DNA and microRNA from body fluids including urine with high accuracy, with AI technology, the company develops innovative tests that enable ultra-early detection, early treatment, and early recovery from cancer. By widely delivering the power of biotechnology and AI to society, Craif promotes its vision of "realizing a society where people live out their natural lives."

【Company Profile】

Company Name: Craif Inc. (Reading: Kuraifu)

Representative: Ryuichi Onozaki, Representative Director

Established: May 2018

Capital: 100 million yen (as of April 1, 2025)

Business: Research and development of next-generation tests for early detection of diseases and realization of personalized medicine, primarily in the field of cancer; provision of urine cancer risk test "MySignal®︎"

Headquarters: THE PORTAL iidabashi B1F, 8-30 Shinkawa, Shinjuku-ku, Tokyo

URL: https://craif.com/